WR GREco, WE DEMBINSKI. Fundamental concepts in the assessment of interaction of biological response modifiers with other agents. Can J Infect Dis 1992;3(Suppl B):60B-68B. The universal response surface approach (uRSA) was developed to assess the nature and intensity of drug interactions. ie. synergism. antagonism and additivity. URSA consists of fitting a concentration-effect surface to experimental data with maximum likelihood approaches, with the estimation of parameters, including: ID5os, concentration-effect slopes and the synergism-an tagonism parameter o.. When o. is positive. synergism is indicated. when o. is negative. antagonism is indicated and when o. is zero. additivity is indicated . 
USE

T HE ASSESSMENT OF THE JOINT EFFECI'S OF DRUGS OR
other agents is ubiquitous in biology and medicine. The claim of synergism for combinations which include biological response modifiers (BRMs) is especially prevalent. For example, a search of the biomedical literature with MEDLJNE from 1983-90 found 14,863 citations in English for synergism, 3560 citations for tumour necrosis factor (TNF). a specific BRM, and 480 citations for the joint occurrence of the two terms. This report discusses several general issues surrounding the highly controversial topic of synergism, and describes an application of a new approach, universal response surface approach (URSA) (1-4) to the quantitative assessment of agent interactions. The specific application of URSA is to a set of 45 individual in vitro growth inhibition experiments in which TNF is combined with one of nine other agents using one of five different schedules of administration. Figure 1 describes the steps necessary to assess the nature of drug interactions, ie, synergism, antagonism and additivity. With synergism one observes a more intense pharmacological effect for a combination of active agents than one would predict from a good knowledge of the individual actions of the agents, with antagonism one observes a less intense effect and with additivity one observes the predicted effect.
UNIVERSAL REPONSE SURFACE APPROACH
Step 1 is to choose a good concentration-effect (doseresponse) structural model for each agent when applied individually. A common choice is the nonlinear form of the median-effect model (5, 6) shown in Figure 2 for an inhibitory drug. This equation is fundamen!ally the same as the Hill-Sigmoid-Emax equation (7) (8) (9) (10) . In this equation. E is the measured effect (response), such as the number of cells remaining in a culture vessel after drug exposure; Dis concentration of drug; Emax is the full range of response which can be affected by the drug; Dm is the median effective dose of drug (or IDso); and m is a slope parameter. When m is negative, the curve falls with increasing drug concentration; when m is positive, the curve rises with increasing drug concentration. The specific curve in Figure 2 was simulated with the three parameters, Emax, Dm and m, assigned values of 100, 1 and -2, respectively. The concentration-effect curve in Figure 2 can be thought of as an ideal curve formed by data with no discernible variation, or as the true curve known only to God or to Mother Nature, or as the average curve formed by a billion data points at each of a billion evenly spaced concentrations.
Since real experiments always generate data which do not fall on the ideal curve, step 2 in Figure 1 is to choose an appropriate data variation model. Model candidates include the normal distribution for continuous data, such as found in growth assays in which the absorbance of a dye bound to cells is the measured signal; the binomial distribution (11) for proportions of failures or successes, such as in acute toxicology experiments; and the Poisson distribution for low numbers of counts, such as in clonogenic assays. A composite model is formed from one structural model plus one data variation model and eventually is used for fitting to real experimental data.
In step 3, most approaches can be categorized into one of two main strategies. In step 3a, a structural model is derived for joint action of two or more agents with the assumption of no interaction (additivity). Then after the experiment is designed and conducted, data from the combination of agents are compared with predictions of joint action with no interaction. In contrast, in step 3b, a structural model is derived for joint action which includes interaction terms. After the experiment is designed and conducted, the full interaction model is fit to all of the data at once, and interaction parameters are estimated. Both the left-and right-hand strategies end in a set of guidelines for making conclusions. Examples of approaches which employ the left-hand strategy include the classical isobologram approach (12) . the method of Gessner (13) . the methods of Berenbaum (14, 15) and the method of Chou (5, 6 ). Examples of a pproaches which employ the right-hand strategy include URSA ( 1-4) and the response surface approaches of Carter (16) .
Although most, and possibly all, approaches for assessing drug combinations may fall under the scheme presented in Figure 1, pharmacologists usually stress structural models, eg, the approach of Chou (5, 6) , whereas the approaches developed by statisticians usually stress data variation models, eg, the approaches of Finney based on Probit analysis (17) . There are differences in the definitions of key terms, especially that of synergism. Some approaches only yield a qualitative conclusion (synergism, antagonism or additivity), such as the classical isobologram approach, whereas others also provide a quantitative measure of the intensity of the interaction, such as URSA. There are differences in the degree of mathematical and statistical rigor, ie, some approaches are performed entirely by hand (eg, the classical isobologram approach), whereas others require a computer (eg, URSA). Some approaches employ parametric models (1 -4), whereas others emphasize nonparametric models (18) . The suggested designs for experiments differ widely among the different approaches. It is, therefore, not surprising that it is possible to generate widely differing conclusions on the nature of a specific drug interaction when applying different methods to the same data set. 
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BIOMEDICAL RATIONALE
TNF was discovered (and is best known as) a protein which causes hemorrhagic necrosis and complete regression of some murine and human cancer cells transplanted into mice (26, 27) . Experimental evidence has accumulated which indicates that TNF also plays a key role in the body's response to infection, injury and inflammation (28) . It is an important factor for the host defence system (29), graft-versus-host disease (30) , differentiation of B cells (31) , regulation of expression of human immunodeficiency virus (32) and numerous other processes (33) . Effects ofTNF have been linked to the arachidonic acid cascade (34) . TNF has been reported to cause the activation of phospholipase A2 in osteoblasts (35) , synovial cells (36) and fibroblasts (37) . Phospholipase A2 releases arachidonate which is converted into leukotrienes by the action of 5-lipoxygenase, or into prostaglandins or thromboxane by the action of cyclooxygenase. Prostaglandins and other eicosanoids rapidly alter the activity of the cells in which they are synthesized and the activity of adjoining cells (55) . Arachidonate metabolites, thus, are considered second messengers. Glucocorticoids, quinacrine and other inhibitors of phospholipase A2 have been found to decrease the cytolytic activity of TNF (38) . These findings imply involvement of phospholipase A2 and/or
arachidonic acid and/or its metabolites in TNF-mediated processes. In an attempt to increase TNF efficacy and to gain more insight into the mechanisms of action ofTNF, studies were conducted to investigate the effect of a set of eicosanoid synthesis inhibitors (more specifically, a set of cyclooxygenase and/or Hpoxygenase inhibitors) given in various schedules on the cytolytic/ antiproHferative activity ofTNF. a is positive, synergism is indicated; when a is negative, antagonism is indicated; when a is zero, no interaction (or additivity) is indicated. The equation, along with these three assignments, comprises the rigorous quantitative set of interaction definitions promised in the 'Introduction'.
MATERIALS AND METHODS
Chemicals
The equation allows the slopes of the concentrationeffect curves for the two drugs to be unequal. The equation was derived (1) with the assumption that each individual concentration-effect curve follows the equation presented in Figure 2 , using an adaptation (1) of the guidelines ofBerenbaum (14) . A convention used in the equation is that as drug concentration(s) increases, the measured response (absorbance) decreases; the slope parameter, m, is negative.
The weighting factor for each data point was equal to the reciprocal of the square of the predicted response, with two exceptions. To avoid overweighting data near the limit of detection, if the predicted response was less than 4% of the maximum response, then the weighting factor was assigned a relative value of 1/(0.04Emax) 2 .
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648 Also, to avoid overweighting poorly fit data for some experiments when the estimated a was negative (antagonism), if the observed effect was less than the 4% cutpoint and the predicted effect was greater than 20% of the maximum effect, then the weighting factor was assigned a value of zero. All weights were normalized such that the sum of the final weights for one experiment equalled the number of data points. Equation 1 was fitted to data using custom software called SYNFIT which was written in the computer language, MicroSoft FORTRAN (MicroSoft Corp. Washington). SYNFIT uses a version of the Marquardt algorithm (24) for nonlinear regression as modified by Nash (40) . The output of the program includes parameter estimates, asymptotic standard errors, 95% confidence limits for the parameters, residual analyses and twodimensional graphs. Since the equation is not in closed form , a one-dimensional bisection root finder (eg, 41) was used to calculate predicted values of E. The SAS/ PC software package, Version 6 (42), was used to generate the three-dimensional graphs of Figure 4 . All software was run on IBM PC-compatible microcomputers. (Inquiries regarding distribution of the custom software package, SYNFIT, should be addressed to WR Greco.)
RESULTS
A total of 45 experiments was conducted: nine different compounds, all with effects on arachidonic acid metabolism, were combined with TNF for the five different schedules of administration. Figures 4 and 5 Figure 4 , and for the other experiments which showed either synergism or additivity, the overall fit was good. The main systematic deviations of the surface from the points occur for the example of antagonism, TNF plus esculetin, (schedule B) in the region of joint high concentrations of both compounds. This systematic poor fit at joint high concentrations also occurred for other antagonistic combinations in this set of experiments.
Clearly, the antagonism model is only useful in this set of experiments for smaller joint concentrations. Figure 5 is a two-dimensional isobolographic representation at the 50% effect level of the three-dimensional surfaces in Figure 4 . When the isoeffect contour bows downward, synergism is indicated, when it bows upward, antagonism is indicated. and when it is a straight diagonal line, additivity is indicated. The ordinate and abscissa are drug concentrations normalized by their respective ID5os. It should be emphasized that the isobols in Figure 5 are not hand drawn, but rather were simulated from the equation using the parameters estimated from fitting the equation to the data. The degree of bowing, a geometric and visual indication of the intensity of interaction, is related to the magnitude of the interaction parameter a (1). The isobols in Figure 5 can also be described as slices through the three-dimensional surfaces of Figure 4 at the 50% effect level.
The parameter estimates with associated standard errors from the fit of equation 1 to the data are listed in Table 1 . Note that m ost of the standard errors are from 5 to 20% of the estimated parameter, indicating a good overall fit of the model to the data. The 95% confidence intervals (the range from the parameter estimate minus about twice the standard error to the estimate plus about twice the standard error, 3) for a provide a simple quantitative test to confirm the qualitative type of interaction. For example, the 95% confidence interval for a for the combination of BW-755C p lus TNF was 1.08 to 5.19. Since the interval is positive and does not encompass zero, synergism is concluded. For the combination of TNF plus esculetin, schedule B, the 95% confidence interval was from -0.370 to -0. 161. Since the interval is negative and does not encompass zero, antagonism is concluded. For the combination ofTNF p lus phenidone, schedule A, the 9 5% confidence interval was from -0.0733 to 0.0674. Since the interval is small and encompasses zero, neither synergism nor antagonism can be concluded, and thus, a default conclusion of no interaction (or additivity) is made. Figure 6 is a summary of the results for all 45 experiments. The 95% confidence intervals for a., the interaction parameter, are plotted for all combinations of TNF with nine different drugs (from three classes) administered via five schedules. Overall, the class of compound (cycloox:ygenase inhibitor, lipox:ygenase inhibitor or cyclo-and lipox:ygenase inhibitor) did not seem to influence the pattem of interactions. BW-755C (cyclo-and lipox:ygenase inhibitor, 43), nafazatrom (lipox:ygenase inhibitor, 46). phenidone (cyclo-and lipoxygenase inhibitor, 44) and NDGA (lipox:ygenase inhibitor, 47) seemed to interact the most synergistically with TNF, whereas timegadine (cyclo-and lipox:ygenase inhibitor, 48). Ro 20-5720 (cycloox:ygenase inhibitor, 49), ibuprofen (cycloox:ygenase inhibitor, 50) and indomethacin (cycloox:ygenase inhibitor, 51) seemed to interact the most antagonistically with TNF. Four drugs, ibuprofen, Ro 20-5720, indomethacin and esculetin showed both antagonism at some schedules and synergism at other schedules. The main tendency showed by this group of nine drugs, when used in combination with TNF, was for a. (the degree of syner-66B gistic interaction) to increase from schedule A to E. Thus, overall, exposing cells to TNF 24 h before a second drug (see Figure 3 ) seemed to enhance synergism, whereas exposing cells to the second drug prior to TNF seemed to enhance antagonism. Table 2 showcases the ID5os and ms (slope parameters) for the concentration-effect surfaces, estimated from fitting Equation 1 to the raw data from each of the 45 experiments. Note that there is one ID5o and one m listed for each second drug at each schedule, but that forTNF, which was present in every experiment, a mean and standard error were calculated for each schedule from the individual estimates from nine experiments. Some trends are evident. The slope parameter, m, was much smaller in magnitude (a shallower slope) for TNF, a BRM, than for the nine other compounds in this system. There is no clear overall pattem for the magnitude of the slope parameters across drug class or across schedule. Overall, the smallest ID5os (highest potencies) for the second drugs were found with schedule C, and forTNF with schedules A, Band D. The largest ID5os (smallest potencies) for the second drugs were found with schedules D and E, and for TNF with schedule E. However, there are numerous exceptions to these generalizations for specific compounds and schedules.
DISCUSSION
A brief description of the URSA (1 -4) has been presented. Since BRMs will most likely be applied therapeutically in combination with other agents, rigorous quantitative approaches to the assessment of BRM interactions at the in vitro, in vivo and clinical levels are critical. Feedback among these levels of investigation is facilitated by rigorous quantitative descriptions (mathematical models).
The specific set of experiments presented, that of TNF plus nine different compounds, each which interfere with arachidonic acid metabolism, against murine L929 cells in vitro, may serve as a paradigm for work with TNF combinations in other biological and biomedical systems, as well as for work with other combinations of BRMs and chemotherapeutic agents. However, some comments on definitions. classifications and semantics must be included here. It should be noted that the classification of eicosanoid synthesis inhibitors (three groups: cycloox:ygenase, lipox:ygenase, and cycloand lipox:ygenase inhibitors) used in this report is not absolute and may not be useful for all biological systems. Also, although the nine eicosanoid synthesis inhibitors used in this study all inhibited the proliferation of L929 cells, none of them is commonly classified or used clinically as anticancer chemotherapeutic agents.
The general pattems seen in Table 2 for the ID5os and slope parameters across drug classes and schedules may reflect complex interplays among the proliferative state of the cells at the time of drug ex- posure, the length of drug exposure, the influence of the cell rinsing procedure, and the differential heterogeneity of the cells to the cytotoxic and cytostatic effects of the 10 inhibitory compounds. Overall, the concentration-effect slopes were much steeper for the nine eicosanoid synthesis inhibitors in this study than has been observed in other studies of anticancer chemotherapeutic drugs by the authors' group (eg,l,2,52,53). The overall main conclusion of this study is that the exposure of cells to TNF, before the exposure to these second agents, enhances the potential for synergism. Since it is well known from many other studies that both TNF and the other nine compounds in this report have profound effects on arachidonic acid-associated pathways (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (43) (44) (45) (46) (47) (48) (49) (50) (51) . it is reasonable to hypothesize that lhe observed empirical interactions between TNF and the other agents were due to biochemical interactions in the arachidonic acid cascade. Characterization of lhe specific points of biochemical interaction will require an intensive research effort. For therapeutic applications of combinations of TNF (or anti-TNF monoclonal antibodies, eg, 54) with inhibitors of cyclooxygenase and/or lipoxygenase, the order of administration of the agents may be critical. It may be useful in future clinical investigations of such combinations to explore the efficacy of different schedules.
